EL7.AI
StocksMedium•17 November 2026•
1 min read

Rein Therapeutics Reports Q3 2026 Results and Phase 2 RENEW Trial Data

Key Facts

1Rein Therapeutics reported Q3 2026 financial results and encouraging preliminary blinded data from its Phase 2 RENEW trial of LTI-03.

Rein Therapeutics reported Q3 2026 financial results and encouraging preliminary blinded data from its Phase 2 RENEW trial of LTI-03. Benzinga reported that the company provided a combined update on its clinical pipeline progress and quarterly fiscal health to investors, with the trial specifically targeting idiopathic pulmonary fibrosis.

RNTX closed at $0.4 on November 16, 2026, after reaching a day high of $0.5 and a day low of $0.2844. These financial results for Rein Therapeutics come at a stage where clinical trial outcomes are typically the primary focus for biotech investors compared to standard fiscal performance.

Open on chart